David de Graaf Appointed as a Scientific Advisory Board Member for Massachusetts Institute of Technology (MIT)’s Center for Cancer Systems Biology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Selventa™, a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, today announced that the Company’s Chief Executive Officer, David de Graaf, has recently been appointed as a Scientific Advisory Board member for the MIT’s Center for Cancer Systems Biology (CCSB) in the National Cancer Institute’s Integrative Cancer Biology Program (ICBP).